GLMD · Galmed Pharmaceuticals Ltd.
$0.51
-0.01 (-1.84%)
At close · Aug 17
Market Cap
$4.24M
Shares
8.26M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.51
Open$0.52
Day$0.50–0.61
52W close$0.47–1.61
Avg vol 30d685K
Short int147K · 1.8% float · 1.0d
Short vol44%
Last earningsDec 31, 2021
DataAug 2024–Aug 2026
Raw chart and full-history price indicators begin at the captured split on Aug 30, 2024; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−28%
below
Price vs 50-day avg
−9%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
4%
near low
Momentum
relative strength
1-month return
0%
trailing
6-month return
−11%
trailing
YTD return
−32%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-13% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.78% of float · ▲ +386.5% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
14 holders — mid 3-yr range
Squeeze score
51
elevated · 0–100
Fundamentals
EPS growth
−70%
Y/Y
Free cash flow
$-6.3M
Balance sheet
$4.0M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−71%
past year
ATR
10.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−28%
Bearish
Price vs 50-day avg
−9%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-13% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.78% of float · ▲ +386.5% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $1 · 4%
Range high $2
vs 200-day avg -28%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GLMD
this stock
Galmed Pharmaceuticals Ltd.
|
$4.24M | -31.6% | +132.3% | — | 1.8% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +19.3% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +13.7% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.4% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +17.5% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
14
- % held
- 1.9%
- Net QoQ
- +10.0K sh
- Top holder
- CITADEL ADVISORS LLC
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Aug 30, 2024; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GLMD | -13.4% | -0.3% | -10.7% | -17.3% | -31.6% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | -13.4% | -4.4% | -23.1% | -20.8% | -45.0% |
Key facts
CIK
1595353
CUSIP
M47238148
13F (30d)
13 filings
13 filers
Visit website
Investor relations